| Dr Andreas C Kyprianou, MD | |
|
1345 W Bay Dr Ste 2-5, Largo, FL 33770-2282 | |
| (727) 441-4526 | |
| (727) 266-4590 |
| Full Name | Dr Andreas C Kyprianou |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 26 Years |
| Location | 1345 W Bay Dr Ste 2-5, Largo, Florida |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1639126105 | NPI | - | NPPES |
| Z82074 | Other | AZ | MEDICARE |
| 875891 | Medicaid | AZ |
| Facility Name | Location | Facility Type |
|---|---|---|
| Largo Medical Center | Largo, FL | Hospital |
| Morton Plant Hospital | Clearwater, FL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Suncoast Chest Physicians Llc | 1951685940 | 6 |
News Archive
A new study provides a timely answer to many of these fears, by reporting on the results of an analysis of over 31,000 vaccine recipients with respect to immediate adverse effects, reported within 21 days, of the first and/or second doses of the vaccine.
Hovione has been advised by Daiichi Sankyo Company Ltd that Inavir(R) has been launched in Japan. Inavir(R) is an inhalation powder which is delivered by the TwinCaps(R) inhaler to treat influenza. TwinCaps(R) was specifically designed by Hovione for this indication and is licensed to Daiichi Sankyo and to Biota Holdings Ltd.
Gilead Sciences, Inc. today announced the initiation of a Phase 2 clinical trial evaluating GS-7340 for the treatment of HIV-1 infection in treatment-naïve adults. GS-7340 is a novel prodrug of tenofovir, the active agent in Viread.
The second phase of a clinical trial testing a new stem-cell-based therapy on injured heart muscle has been launched by researchers at The University of Texas Medical School at Houston. It is the only study site in the Texas Medical Center.
› Verified 1 days ago
| Entity Name | Suncoast Chest Physicians Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417490822 PECOS PAC ID: 1951685940 Enrollment ID: O20170313001394 |
News Archive
A new study provides a timely answer to many of these fears, by reporting on the results of an analysis of over 31,000 vaccine recipients with respect to immediate adverse effects, reported within 21 days, of the first and/or second doses of the vaccine.
Hovione has been advised by Daiichi Sankyo Company Ltd that Inavir(R) has been launched in Japan. Inavir(R) is an inhalation powder which is delivered by the TwinCaps(R) inhaler to treat influenza. TwinCaps(R) was specifically designed by Hovione for this indication and is licensed to Daiichi Sankyo and to Biota Holdings Ltd.
Gilead Sciences, Inc. today announced the initiation of a Phase 2 clinical trial evaluating GS-7340 for the treatment of HIV-1 infection in treatment-naïve adults. GS-7340 is a novel prodrug of tenofovir, the active agent in Viread.
The second phase of a clinical trial testing a new stem-cell-based therapy on injured heart muscle has been launched by researchers at The University of Texas Medical School at Houston. It is the only study site in the Texas Medical Center.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Andreas C Kyprianou, MD 5151 E Broadway Rd Ste 107, Mesa, AZ 85206-1346 Ph: (602) 258-4951 | Dr Andreas C Kyprianou, MD 1345 W Bay Dr Ste 2-5, Largo, FL 33770-2282 Ph: (727) 441-4526 |
News Archive
A new study provides a timely answer to many of these fears, by reporting on the results of an analysis of over 31,000 vaccine recipients with respect to immediate adverse effects, reported within 21 days, of the first and/or second doses of the vaccine.
Hovione has been advised by Daiichi Sankyo Company Ltd that Inavir(R) has been launched in Japan. Inavir(R) is an inhalation powder which is delivered by the TwinCaps(R) inhaler to treat influenza. TwinCaps(R) was specifically designed by Hovione for this indication and is licensed to Daiichi Sankyo and to Biota Holdings Ltd.
Gilead Sciences, Inc. today announced the initiation of a Phase 2 clinical trial evaluating GS-7340 for the treatment of HIV-1 infection in treatment-naïve adults. GS-7340 is a novel prodrug of tenofovir, the active agent in Viread.
The second phase of a clinical trial testing a new stem-cell-based therapy on injured heart muscle has been launched by researchers at The University of Texas Medical School at Houston. It is the only study site in the Texas Medical Center.
› Verified 1 days ago
Dr. Julie Bard Fogarty, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 8787 Bryan Dairy Rd Ste 320, Largo, FL 33777 Phone: 727-394-5650 Fax: 813-635-7939 | |
Dr. James F. Rivenbark, M.D. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 1301 2nd Ave Sw, Largo, FL 33770 Phone: 727-584-7706 Fax: 727-586-6018 | |
Randal G Worth, DO Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 13644 Walsingham Rd, Largo, FL 33774 Phone: 727-595-2519 Fax: 727-595-3872 | |
Dr. Rubaiya Mallay, D.O. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 13644 Walsingham Road, Largo, FL 33774 Phone: 727-595-2519 Fax: 727-595-3872 | |
Tatjana Webster, M.D. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 901 Clearwater-largo Rd N, Largo, FL 33770 Phone: 727-584-4533 Fax: 727-581-7386 | |
Andi Canhasi, Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 201 14th St Sw, Largo, FL 33770 Phone: 727-588-5704 Fax: 727-585-7205 | |
Dr. Miranda Giusti, D.O. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 3600 Oak Manor Ln Apt 46, Largo, FL 33774 Phone: 727-489-3305 Fax: 727-499-9559 |